TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants Who Were Lymphedema-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of end tidal CO2 catheter for six hours or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma HCV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose levels during oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 28 day all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects showing HBV DNA negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to change of systemic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Joint space width measured on weight-bearing radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain subscale of the Knee Injury and Osteoarthritis Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Management Score on Transfer Scenario n°1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Cost (Oxygen Consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HCV Viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HCV protease gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency between VMO and VL electromyographic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time taken to return to work/school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Detection and communication of abnormal patient physiological states
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of OGX-427
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety profile of OGX-427
Endpoint domain: Adverse events/effects
Primary endpoint: Survival Rate of Participants
Endpoint domain: Mortality/survival
Primary endpoint: Change in New York Heart Association (NYHA) functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 6 mint walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mini-Mental State Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel [AUC(0-∞)] in Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel [AUC(0-∞)] in Cycle 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in WOMAC Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraocular pressure (IOP)-lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
Endpoint domain: Adverse events/effects
Primary endpoint: sensory pressure thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory intensity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implantation rate per embryo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fractional synthetic rate of muscle growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Peak Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal incontinence quality of life scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in resting state BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in resting state EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in white matter integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of >50% restenosis at the treated segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Non perfused volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of participants with treatment related acute adverse events post vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants with any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants with serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: improvement of dry eye symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in nutrition and physical activity goals met
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Myocardial Infarct Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in log10 HIV-1 RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Hooper's Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake relative difference on parametric mean registered SPECT map
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of hours per night of device use
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Difference in partial pressure of carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major cardio-vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Sylatron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite end-point of Calcium (Ca), Phosphorus (P), and Calcium-Phosphorus product (Ca*P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Eyes With Corneal Graft Failure Within 3 Years of Surgery
Endpoint domain: Mortality/survival
Primary endpoint: Drain output at 23 hours post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Time Point with Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Concentration-Time Curve (AUC) from Time Zero extrapolated to infinity (AUCInf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant and young child feeding practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4+ T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychophysical measures of imitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO Functional Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of pain alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Report of Adverse Events occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop of Blood Pressure at Night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluid overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak cough flow (max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Max Inspiratory Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Max Expiratory Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of NF1 patients developed PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tumorigenesis in multiple myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mobilisation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAA morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee joint space difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximally tolerated dose of mebendazole
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experience 1 or More Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Pulmonary Hypertension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of total score on ADHD RS-IV-J
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: microvessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apoptosis of endothelial and tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of TMC207 and its M2 metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm Blood-flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete discontinuation of inappropriate prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Early and Sustained (Antidepressant) Response (ESR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR12) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Stomach Upset
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Abdominal Pain
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Pentacam readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of coordination between STN and cortical regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate in Juvenile Myelomonocytic Leukemia (JMML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrence of convulsions
Endpoint domain: Adverse events/effects
Primary endpoint: regional brain insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Single leg hamstring bridge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in total volume of all nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantitative measure of balance via Biodex balance system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in fluorescein corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ocular discomfort (worst symptom, VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of primary serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quadriceps and hip abductor muscles strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 30s sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee pain: Visual Analogy Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Melbourne Assessment 2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation free days to day 28 (VFD28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe adverse events (SAEs) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of perineal irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Showing Seroconversion to All HPV Four Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Visits to Primary Care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Visits to Secondary Care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sexual Pleasure Scale Score for Fitted Versus Standard Condoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Participants Preferring Fitted Condoms to Standard Condoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Condom Failure for Anal Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and tolerability of Ad-RTS-hIL-12 immunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mean transcutaneous carbon dioxide pressure (PtcCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal transcutaneous carbon dioxide pressure (PtcCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PtcCO2 during ≥ 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraoperative hemodynamic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BLAST-50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Single Leaflet Device Attachment (SLDA) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: No of Participants With Acute Procedural Success (APS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fall incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Wave Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients developing severe sepsis or septic shock due to CLABSI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with venous thrombosis in the limb where the central venous catheter
Endpoint domain: Adverse events/effects
Primary endpoint: Short- and long-term point prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of Prolonged Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substantivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in California Verbal Learning Test - II (CVLT-II) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) - Story Memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Wechsler Memory Scale III - Faces II performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease control rate as assessed by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum 25 (OH) D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oxygen use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of cone-beam CT vs CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of molecular aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac index in l/min/m
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular ejection fraction (EF) in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CEU (Cerebral Endothelial Function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADHD metabolomic's signature of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ADHD metabolomic's signature of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in delayed recall memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in serum brain derived neurotrophic factor (BDNF) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain intensity/consumption of pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy Rates Based on Pearl Index (PI) for 91-Day Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy Rates Based on Pearl Index (PI) for 28-Day Cycle-Equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Adverse events related to NAVX-010
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in cardiac rhythm monitored by telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes